Logo image of REPL

REPLIMUNE GROUP INC (REPL) Stock Overview

NASDAQ:REPL - US76029N1063 - Common Stock

6.33 USD
+0.52 (+8.95%)
Last: 9/5/2025, 8:00:02 PM
6.16 USD
-0.17 (-2.69%)
After Hours: 9/5/2025, 8:00:02 PM

REPL Key Statistics, Chart & Performance

Key Statistics
52 Week High17
52 Week Low2.68
Market Cap494.12M
Shares78.06M
Float75.72M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.24
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO07-20 2018-07-20
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


REPL short term performance overview.The bars show the price performance of REPL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

REPL long term performance overview.The bars show the price performance of REPL in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of REPL is 6.33 USD. In the past month the price increased by 15.51%. In the past year, price decreased by -38.96%.

REPLIMUNE GROUP INC / REPL Daily stock chart

REPL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.07 375.50B
AMGN AMGEN INC 13.01 152.70B
GILD GILEAD SCIENCES INC 14.86 142.76B
VRTX VERTEX PHARMACEUTICALS INC 23.38 101.56B
REGN REGENERON PHARMACEUTICALS 12.56 60.77B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.25B
ARGX ARGENX SE - ADR 80.99 45.95B
ONC BEONE MEDICINES LTD-ADR 6.89 40.63B
INSM INSMED INC N/A 30.67B
BNTX BIONTECH SE-ADR N/A 27.03B
NTRA NATERA INC N/A 23.06B
BIIB BIOGEN INC 8.79 20.62B

About REPL

Company Profile

REPL logo image Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

Company Info

REPLIMUNE GROUP INC

500 Unicorn Park Dr

Woburn MASSACHUSETTS 01801 US

CEO: Philip Astley-Sparke

Employees: 331

REPL Company Website

REPL Investor Relations

Phone: 17812229600

REPLIMUNE GROUP INC / REPL FAQ

What is the stock price of REPLIMUNE GROUP INC today?

The current stock price of REPL is 6.33 USD. The price increased by 8.95% in the last trading session.


What is the ticker symbol for REPLIMUNE GROUP INC stock?

The exchange symbol of REPLIMUNE GROUP INC is REPL and it is listed on the Nasdaq exchange.


On which exchange is REPL stock listed?

REPL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for REPLIMUNE GROUP INC stock?

15 analysts have analysed REPL and the average price target is 7.29 USD. This implies a price increase of 15.1% is expected in the next year compared to the current price of 6.33. Check the REPLIMUNE GROUP INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is REPLIMUNE GROUP INC worth?

REPLIMUNE GROUP INC (REPL) has a market capitalization of 494.12M USD. This makes REPL a Small Cap stock.


How many employees does REPLIMUNE GROUP INC have?

REPLIMUNE GROUP INC (REPL) currently has 331 employees.


What are the support and resistance levels for REPLIMUNE GROUP INC (REPL) stock?

REPLIMUNE GROUP INC (REPL) has a support level at 5.53 and a resistance level at 11.45. Check the full technical report for a detailed analysis of REPL support and resistance levels.


Is REPLIMUNE GROUP INC (REPL) expected to grow?

The Revenue of REPLIMUNE GROUP INC (REPL) is expected to grow by 300% in the next year. Check the estimates tab for more information on the REPL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy REPLIMUNE GROUP INC (REPL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does REPLIMUNE GROUP INC (REPL) stock pay dividends?

REPL does not pay a dividend.


When does REPLIMUNE GROUP INC (REPL) report earnings?

REPLIMUNE GROUP INC (REPL) will report earnings on 2025-11-10.


What is the Price/Earnings (PE) ratio of REPLIMUNE GROUP INC (REPL)?

REPLIMUNE GROUP INC (REPL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.24).


What is the Short Interest ratio of REPLIMUNE GROUP INC (REPL) stock?

The outstanding short interest for REPLIMUNE GROUP INC (REPL) is 25.35% of its float. Check the ownership tab for more information on the REPL short interest.


REPL Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to REPL. When comparing the yearly performance of all stocks, REPL is a bad performer in the overall market: 95.04% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

REPL Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to REPL. While REPL seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

REPL Financial Highlights

Over the last trailing twelve months REPL reported a non-GAAP Earnings per Share(EPS) of -3.24. The EPS increased by 0.92% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -59.68%
ROE -83.22%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%-21.79%
Sales Q2Q%N/A
EPS 1Y (TTM)0.92%
Revenue 1Y (TTM)N/A

REPL Forecast & Estimates

15 analysts have analysed REPL and the average price target is 7.29 USD. This implies a price increase of 15.1% is expected in the next year compared to the current price of 6.33.

For the next year, analysts expect an EPS growth of -10.21% and a revenue growth 300% for REPL


Analysts
Analysts72
Price Target7.29 (15.17%)
EPS Next Y-10.21%
Revenue Next Year300%

REPL Ownership

Ownership
Inst Owners106.63%
Ins Owners2.02%
Short Float %25.35%
Short Ratio1.75